Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGIOS PHARMACEUTICALS, INC.

(AGIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
44.28(c) 45.82(c) 47.58(c) 47.99(c) 48.55(c) Last
365 780 241 709 310 113 338 651 320 517 Volume
-4.32% +3.48% +3.84% +0.86% +1.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 4,75 M - -
Net income 2021 1 607 M - -
Net cash position 2021 1 125 M - -
P/E ratio 2021 1,87x
Yield 2021 -
Sales 2022 55,0 M - -
Net income 2022 -357 M - -
Net cash position 2022 790 M - -
P/E ratio 2022 -7,00x
Yield 2022 -
Capitalization 2 862 M 2 862 M -
EV / Sales 2021 366x
EV / Sales 2022 37,7x
Nbr of Employees 562
Free-Float 80,9%
More Financials
Company
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD).... 
More about the company
Ratings of Agios Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about AGIOS PHARMACEUTICALS, INC.
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
10/21AGIOS PHARMACEUTICALS : to Webcast Conference Call of Third Quarter 2021 Financial Results..
GL
08/30Agios To Present at September Investor Conferences
GL
08/17AGIOS PHARMACEUTICALS : Says US FDA Accepts Mitapivat New Drug Application for Priority Re..
MT
08/17AGIOS PHARMACEUTICALS : Announces FDA Acceptance and Priority Review of New Drug Applicati..
AQ
08/17Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Ap..
CI
08/04AGIOS PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/04Agios Pharmaceuticals, Inc. Announces Executive Changes
CI
07/30AGIOS PHARMACEUTICALS : HC Wainwright Adjusts Agios Pharmaceuticals' Price Target to $93 F..
MT
07/30AGIOS PHARMACEUTICALS : Goldman Sachs Cuts Agios Pharmaceuticals to Sell From Neutral, Pri..
MT
07/29AGIOS PHARMACEUTICALS : Posts Wider Net Loss in Q2
MT
07/29AGIOS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
07/29AGIOS PHARMACEUTICALS : Second Quarter 2021 Financial Results Presentation
PU
07/29AGIOS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Change in Dir..
AQ
More news
News in other languages on AGIOS PHARMACEUTICALS, INC.
10/22BB BIOTECH : Gewinnrealisierungen -2-
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
01/19SERVIER : bénéfice net annuel en forte hausse, comparaison favorable
2020Servier achète la division oncologie de la biotech Agios Pharmaceuticals
2020AGIOS PHARMACEUTICALS : vend son portefeuille d'oncologie à Servier, prend 29,5% en préouv..
More news
Analyst Recommendations on AGIOS PHARMACEUTICALS, INC.
More recommendations
Chart AGIOS PHARMACEUTICALS, INC.
Duration : Period :
Agios Pharmaceuticals, Inc. Technical Analysis Chart | AGIO | US00847X1046 | MarketScreener
Technical analysis trends AGIOS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 48,55 $
Average target price 62,43 $
Spread / Average Target 28,6%
EPS Revisions
Managers and Directors
Jacqualyn A. Fouse Chief Executive Officer & Director
Jonathan Prim Biller CFO, Head-Legal & Corporate Affairs
David Paul Schenkein Executive Chairman
Clive Patience Executive Vice President-Technical Operations
Bruce Car Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AGIOS PHARMACEUTICALS, INC.12.05%2 862
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610